Symbols / AYTU Stock $2.15 +4.37% Aytu BioPharma, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NCM
AYTU (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Mr. Joshua R. Disbrow
Exch · Country NCM · United States
Market Cap 23.08M
Enterprise Value 18.18M
Income -34.12M
Sales 56.60M
FCF (ttm) -1.07M
Book/sh 3.27
Cash/sh 2.49
Employees 82
Insider 10d —
IPO Sep 25, 2008
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -43.00
PEG —
P/S 0.41
P/B 0.66
P/C —
EV/EBITDA -6.92
EV/Sales 0.32
Quick Ratio 0.85
Current Ratio 1.12
Debt/Eq 62.08
LT Debt/Eq —
EPS (ttm) -4.61
EPS next Y -0.05
EPS Growth —
Revenue Growth -32.70%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-13
Earnings (prior) 2026-05-13
ROA -3.65%
ROE -97.42%
ROIC —
Gross Margin 64.78%
Oper. Margin -32.74%
Profit Margin -60.17%
Shs Outstand 10.73M
Shs Float 7.61M
Insider Own 8.98%
Instit Own 36.58%
Short Float 5.48%
Short Ratio 14.85
Short Interest 505.37K
52W High 3.07
vs 52W High -29.97%
52W Low 1.46
vs 52W Low 47.26%
Beta —
Impl. Vol. —
Rel Volume 0.62
Avg Volume 47.19K
Volume 29.43K
Target (mean) $9.33
Tgt Median $7.00
Tgt Low $7.00
Tgt High $14.00
# Analysts 3
Recom Strong_buy
Prev Close $2.06
Price $2.15
Change 4.37%
About

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$9.33
Mean price target
2. Current target
$2.15
Latest analyst target
3. DCF / Fair value
$-1.80
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.15
Low
$7.00
High
$14.00
Mean
$9.33

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-12-10 main Ascendiant Capital Buy → Buy $13
2025-09-25 main Maxim Group Buy → Buy $7
2025-09-25 main Ascendiant Capital Buy → Buy $13
2025-07-01 init Lake Street — → Buy $8
2025-06-30 init Ascendiant Capital — → Buy $12
2023-08-09 init Maxim Group — → Buy $5
2023-05-31 reit HC Wainwright & Co. Buy → Buy $20
News
RSS: Latest AYTU news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-10-03 DISBROW JOSHUA R. Chief Executive Officer — 53,946 $0.00 $0
2025-10-03 DOCKERY CARL C Director — 10,000 $0.00 $0
2025-10-03 DISBROW JARRETT T Officer — 32,106 $0.00 $0
2025-10-03 SELHORN RYAN J Chief Financial Officer — 33,743 $0.00 $0
2025-10-03 PYSZCZYMUKA GREG Officer — 12,500 $0.00 $0
2025-10-03 JAIN ABHINAV Director — 10,000 $0.00 $0
2025-10-03 LIU VIVIAN H Director — 10,000 $0.00 $0
2025-06-09 DISBROW JOSHUA R. Chief Executive Officer — 66,666 $2.11 $140,665
2025-06-09 DISBROW JARRETT T Officer — 16,666 $2.11 $35,165
2025-03-31 PYSZCZYMUKA GREG Officer — 209 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total Revenue
66.38
+1.84%
65.18
-39.31%
107.40
+11.10%
96.67
Operating Revenue
66.38
+1.84%
65.18
-39.31%
107.40
+11.10%
96.67
Cost Of Revenue
20.55
+27.42%
16.13
-60.44%
40.77
-8.15%
44.39
Reconciled Cost Of Revenue
18.86
+44.09%
13.09
-64.38%
36.74
-8.34%
40.08
Gross Profit
45.83
-6.57%
49.05
-26.38%
66.63
+27.44%
52.28
Operating Expense
43.29
-10.71%
48.49
-38.59%
78.96
-10.66%
88.39
Research And Development
1.33
-52.11%
2.77
-32.38%
4.09
-67.66%
12.66
Selling General And Administration
38.28
-8.93%
42.04
-40.01%
70.08
+0.28%
69.88
Selling And Marketing Expense
20.91
-5.33%
22.08
-46.72%
41.45
+7.06%
38.71
General And Administrative Expense
17.38
-12.90%
19.95
-30.30%
28.63
-8.14%
31.17
Other Gand A
17.38
-12.90%
19.95
-30.30%
28.63
-8.14%
31.17
Total Expenses
63.84
-1.20%
64.62
-46.03%
119.73
-9.82%
132.77
Operating Income
2.54
+349.03%
0.56
+104.58%
-12.33
+65.85%
-36.10
Total Operating Income As Reported
-7.83
-391.95%
-1.59
+90.68%
-17.07
+84.47%
-109.91
EBITDA
-4.67
-431.79%
1.41
+142.96%
-3.27
+87.39%
-25.96
Normalized EBITDA
7.40
-9.29%
8.16
+345.05%
-3.33
-107.23%
46.07
Reconciled Depreciation
5.38
-20.04%
6.72
-23.71%
8.81
-13.12%
10.15
EBIT
-10.04
-88.79%
-5.32
+56.00%
-12.09
+66.52%
-36.10
Total Unusual Items
-12.07
-78.66%
-6.75
-11949.12%
0.06
+100.08%
-72.03
Total Unusual Items Excluding Goodwill
-12.07
-78.66%
-6.75
-11949.12%
0.06
+100.08%
-72.03
Special Income Charges
-10.36
-276.87%
-2.75
+41.93%
-4.74
+93.57%
-73.63
Other Special Charges
—
0.59
—
-0.17
Impairment Of Capital Assets
—
—
0.00
-100.00%
65.80
Restructuring And Mergern Acquisition
2.10
-2.55%
2.16
+322.50%
-0.97
+41.45%
-1.66
Write Off
8.26
0.00
-100.00%
5.71
-40.92%
9.66
Net Income
-13.56
+14.40%
-15.84
+7.08%
-17.05
+84.33%
-108.78
Pretax Income
-13.74
-32.44%
-10.38
+39.14%
-17.05
+84.34%
-108.89
Net Non Operating Interest Income Expense
-3.70
+26.80%
-5.06
-1.93%
-4.96
—
Interest Expense Non Operating
3.70
-26.80%
5.06
+1.93%
4.96
—
Net Interest Income
-3.70
+26.80%
-5.06
-1.93%
-4.96
—
Interest Expense
3.70
-26.80%
5.06
+1.93%
4.96
—
Other Income Expense
-12.58
-113.78%
-5.88
-2541.49%
0.24
+100.33%
-72.79
Other Non Operating Income Expenses
-0.51
-158.85%
0.87
+372.83%
0.18
+124.31%
-0.76
Gain On Sale Of Security
-1.70
+57.47%
-4.00
-183.54%
4.79
+198.63%
1.60
Tax Provision
0.44
-79.60%
2.14
0.00
+100.00%
-0.11
Tax Rate For Calcs
0.00
+0.00%
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
-2.53
-78.66%
-1.42
0.00
+100.00%
-0.06
Net Income Including Noncontrolling Interests
-13.56
+14.40%
-15.84
+7.08%
-17.05
+84.33%
-108.78
Net Income From Continuing Operation Net Minority Interest
-14.18
-13.27%
-12.52
+26.57%
-17.05
+84.33%
-108.78
Net Income From Continuing And Discontinued Operation
-13.56
+14.40%
-15.84
+7.08%
-17.05
+84.33%
-108.78
Net Income Continuous Operations
-14.18
-13.27%
-12.52
+26.57%
-17.05
+84.33%
-108.78
Net Income Discontinuous Operations
0.62
+118.65%
-3.32
—
—
Normalized Income
-4.65
+35.29%
-7.18
+58.01%
-17.11
+53.53%
-36.81
Net Income Common Stockholders
-13.56
+14.40%
-15.84
+7.08%
-17.05
+84.33%
-108.78
Diluted EPS
-2.16
+24.48%
-2.86
+44.03%
-5.11
+93.19%
-75.00
Basic EPS
-2.16
+24.48%
-2.86
+44.03%
-5.11
+93.19%
-75.00
Basic Average Shares
6.28
+13.39%
5.54
+65.81%
3.34
+127.22%
1.47
Diluted Average Shares
6.28
+13.39%
5.54
+65.81%
3.34
+127.22%
1.47
Diluted NI Availto Com Stockholders
-13.56
+14.40%
-15.84
+7.08%
-17.05
+84.33%
-108.78
Amortization
3.68
+0.00%
3.68
-23.08%
4.79
-18.07%
5.84
Amortization Of Intangibles Income Statement
3.68
+0.00%
3.68
-23.08%
4.79
-18.07%
5.84
Depreciation Amortization Depletion Income Statement
3.68
+0.00%
3.68
-23.08%
4.79
-18.07%
5.84
Depreciation And Amortization In Income Statement
3.68
+0.00%
3.68
-23.08%
4.79
-18.07%
5.84
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total Assets
124.18
+5.15%
118.09
-13.46%
136.46
-0.84%
137.62
Current Assets
79.18
+27.93%
61.89
-12.93%
71.08
+18.61%
59.93
Cash Cash Equivalents And Short Term Investments
30.95
+54.71%
20.01
-12.96%
22.98
+18.72%
19.36
Cash And Cash Equivalents
30.95
+54.71%
20.01
-12.96%
22.98
+18.72%
19.36
Receivables
31.16
+32.43%
23.53
-18.70%
28.94
+33.28%
21.71
Accounts Receivable
31.16
+32.43%
23.53
-18.70%
28.94
+33.28%
21.71
Gross Accounts Receivable
32.34
+27.60%
25.35
-20.61%
31.93
+47.05%
21.71
Allowance For Doubtful Accounts Receivable
-1.19
+34.80%
-1.82
+39.06%
-2.99
0.00
Inventory
11.43
-5.82%
12.14
+1.22%
11.99
+10.56%
10.85
Raw Materials
1.11
+319.17%
0.27
-79.55%
1.30
-28.28%
1.81
Work In Process
1.38
-75.88%
5.72
+93.67%
2.96
+60.83%
1.84
Finished Goods
8.94
+45.33%
6.15
-20.52%
7.74
+7.52%
7.20
Prepaid Assets
—
—
8.05
+9.11%
7.38
Restricted Cash
—
—
—
0.00
Assets Held For Sale Current
0.00
-100.00%
1.12
—
—
Other Current Assets
5.64
+10.61%
5.10
-28.83%
7.16
-10.56%
8.01
Total Non Current Assets
45.00
-19.94%
56.20
-14.04%
65.38
-15.84%
77.69
Net PPE
1.59
+4.66%
1.52
-60.66%
3.87
-38.55%
6.30
Gross PPE
2.31
-36.74%
3.65
-51.70%
7.55
-13.39%
8.72
Accumulated Depreciation
-0.71
+66.40%
-2.12
+42.27%
-3.68
-52.04%
-2.42
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.27
-71.01%
0.94
-16.00%
1.12
-0.27%
1.13
Construction In Progress
—
0.00
-100.00%
0.11
0.00
Other Properties
1.87
-29.92%
2.67
-49.86%
5.32
-19.29%
6.59
Leases
0.16
+368.57%
0.04
-96.50%
1.00
+0.00%
1.00
Goodwill And Other Intangible Assets
42.20
-19.55%
52.45
-11.05%
58.97
-16.51%
70.63
Goodwill
—
—
—
0.00
Other Intangible Assets
42.20
-19.55%
52.45
-11.05%
58.97
-16.51%
70.63
Other Non Current Assets
1.20
-45.98%
2.23
-12.42%
2.54
+232.25%
0.77
Total Liabilities Net Minority Interest
105.21
+16.41%
90.38
-6.93%
97.11
+4.06%
93.31
Current Liabilities
63.06
+1.34%
62.23
-9.83%
69.02
+7.10%
64.44
Payables And Accrued Expenses
38.82
-0.51%
39.02
-20.08%
48.83
+9.38%
44.64
Payables
10.60
+2.78%
10.31
-23.48%
13.48
+22.67%
10.99
Accounts Payable
10.60
+2.78%
10.31
-23.48%
13.48
+22.67%
10.99
Current Accrued Expenses
28.22
-1.70%
28.71
-18.78%
35.35
+5.04%
33.65
Pensionand Other Post Retirement Benefit Plans Current
3.13
-31.96%
4.60
-18.89%
5.67
+19.10%
4.76
Current Debt And Capital Lease Obligation
10.92
+156.82%
4.25
+158.01%
1.65
-57.84%
3.91
Current Debt
10.92
+156.82%
4.25
+158.01%
1.65
-57.84%
3.91
Other Current Borrowings
1.86
+0.00%
1.86
+2084.71%
0.09
-11.46%
0.10
Current Capital Lease Obligation
—
—
—
—
Other Current Liabilities
3.38
-64.50%
9.52
+34.26%
7.09
+32.30%
5.36
Total Non Current Liabilities Net Minority Interest
42.15
+49.72%
28.15
+0.21%
28.09
-2.71%
28.87
Long Term Debt And Capital Lease Obligation
10.89
+0.17%
10.88
-26.07%
14.71
+3.04%
14.28
Long Term Debt
10.89
+0.17%
10.88
-26.07%
14.71
+3.04%
14.28
Long Term Capital Lease Obligation
—
—
—
—
Other Non Current Liabilities
4.92
+8.59%
4.53
-35.07%
6.97
-45.50%
12.80
Stockholders Equity
18.97
-31.57%
27.72
-29.58%
39.36
-11.17%
44.31
Common Stock Equity
18.97
-31.57%
27.72
-29.58%
39.36
-11.17%
44.31
Capital Stock
0.00
+0.00%
0.00
+0.00%
0.00
0.00
Common Stock
0.00
+0.00%
0.00
+0.00%
0.00
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
8.98
+50.30%
5.97
+8.26%
5.52
+186.02%
1.93
Ordinary Shares Number
8.98
+50.30%
5.97
+8.26%
5.52
+186.02%
1.93
Additional Paid In Capital
352.50
+1.38%
347.69
+1.22%
343.49
+3.65%
331.39
Retained Earnings
-333.54
-4.24%
-319.97
-5.21%
-304.13
-5.94%
-287.08
Total Equity Gross Minority Interest
18.97
-31.57%
27.72
-29.58%
39.36
-11.17%
44.31
Total Capitalization
29.86
-22.63%
38.59
-28.62%
54.07
-7.71%
58.59
Working Capital
16.11
+4881.90%
-0.34
-116.33%
2.06
+145.73%
-4.51
Invested Capital
40.78
-4.82%
42.84
-23.10%
55.72
-10.85%
62.50
Total Debt
21.82
+44.19%
15.13
-7.53%
16.36
-10.05%
18.19
Capital Lease Obligations
—
—
—
—
Net Tangible Assets
-23.23
+6.07%
-24.74
-26.13%
-19.61
+25.49%
-26.32
Tangible Book Value
-23.23
+6.07%
-24.74
-26.13%
-19.61
+25.49%
-26.32
Current Provisions
6.81
+40.96%
4.83
-16.36%
5.78
+0.12%
5.77
Derivative Product Liabilities
26.33
+106.62%
12.74
+99.05%
6.40
+256.51%
1.80
Line Of Credit
9.06
+278.41%
2.40
+53.23%
1.56
-59.01%
3.81
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Operating Cash Flow
-1.94
-39.55%
-1.39
+72.94%
-5.13
+82.21%
-28.82
Cash Flow From Continuing Operating Activities
-1.94
-39.55%
-1.39
+72.94%
-5.13
+82.21%
-28.82
Net Income From Continuing Operations
-13.56
+14.40%
-15.84
+7.08%
-17.05
+84.33%
-108.78
Depreciation Amortization Depletion
5.38
-20.04%
6.72
-23.71%
8.81
-13.12%
10.15
Depreciation
5.38
-20.04%
6.72
-23.71%
8.81
-13.12%
10.15
Depreciation And Amortization
5.38
-20.04%
6.72
-23.71%
8.81
-13.12%
10.15
Other Non Cash Items
1.11
-74.82%
4.42
+1198.01%
-0.40
+78.17%
-1.85
Stock Based Compensation
0.58
-75.73%
2.37
-60.75%
6.05
+15.21%
5.25
Provisionand Write Offof Assets
—
—
—
-0.07
Asset Impairment Charge
8.59
+622.29%
1.19
-85.24%
8.06
-89.62%
77.64
Operating Gains Losses
1.70
-61.33%
4.40
+191.88%
-4.79
-1184.99%
-0.37
Gain Loss On Investment Securities
1.70
-57.47%
4.00
+183.54%
-4.79
-2562.78%
-0.18
Change In Working Capital
-5.73
-23.03%
-4.66
+19.64%
-5.80
+46.62%
-10.86
Change In Receivables
-7.63
-246.68%
5.20
+172.71%
-7.15
-209.49%
6.53
Changes In Account Receivables
-7.63
-246.68%
5.20
+172.71%
-7.15
-209.49%
6.53
Change In Inventory
0.38
+107.92%
-4.82
-33.58%
-3.61
-377.83%
1.30
Change In Prepaid Assets
-0.45
-237.08%
0.33
-61.11%
0.85
-62.03%
2.23
Change In Payables And Accrued Expense
1.17
+110.44%
-11.24
-287.63%
5.99
+128.56%
-20.97
Change In Accrued Expense
0.89
+109.67%
-9.16
-354.12%
3.60
+127.12%
-13.29
Change In Payable
0.29
+113.82%
-2.08
-187.08%
2.38
+131.04%
-7.68
Change In Account Payable
0.29
+113.82%
-2.08
-187.08%
2.38
+131.04%
-7.68
Change In Other Working Capital
0.79
-86.50%
5.87
+413.46%
-1.87
-3844.00%
0.05
Investing Cash Flow
-2.56
-678.12%
-0.33
-181.20%
-0.12
+96.40%
-3.25
Cash Flow From Continuing Investing Activities
-2.56
-678.12%
-0.33
-181.20%
-0.12
+96.40%
-3.25
Net PPE Purchase And Sale
0.44
+233.74%
-0.33
—
—
Purchase Of PPE
-0.23
+30.70%
-0.33
—
—
Sale Of PPE
0.67
0.00
—
—
Capital Expenditure
-3.23
-881.16%
-0.33
—
—
Net Business Purchase And Sale
—
—
-0.01
+99.84%
-3.18
Purchase Of Business
—
—
-0.01
+99.84%
-3.18
Net Intangibles Purchase And Sale
-3.00
0.00
—
—
Purchase Of Intangibles
-3.00
0.00
—
—
Net Other Investing Changes
—
-0.33
-181.20%
-0.12
-67.14%
-0.07
Financing Cash Flow
15.44
+1323.69%
-1.26
-114.23%
8.87
+479.80%
1.53
Cash Flow From Continuing Financing Activities
15.44
+1323.69%
-1.26
-114.23%
8.87
+479.80%
1.53
Net Issuance Payments Of Debt
6.67
+452.80%
-1.89
+19.44%
-2.35
+55.07%
-5.22
Issuance Of Debt
8.53
-38.37%
13.83
0.00
-100.00%
15.00
Repayment Of Debt
-1.86
+88.19%
-15.72
-570.16%
-2.35
+88.40%
-20.22
Long Term Debt Issuance
1.86
-85.72%
13.00
0.00
-100.00%
15.00
Long Term Debt Payments
-1.86
+88.19%
-15.72
-16277.08%
-0.10
+99.40%
-16.10
Net Long Term Debt Issuance
0.00
+100.00%
-2.72
-2735.42%
-0.10
+91.28%
-1.10
Short Term Debt Issuance
6.67
+701.44%
0.83
—
152.24
Short Term Debt Payments
—
—
-2.25
+45.40%
-4.12
Net Short Term Debt Issuance
6.67
+701.44%
0.83
+136.98%
-2.25
+45.40%
-4.12
Net Common Stock Issuance
14.84
+328.04%
3.47
-77.74%
15.57
+33.19%
11.69
Proceeds From Stock Option Exercised
—
—
—
—
Net Other Financing Charges
-6.07
-113.63%
-2.84
+34.86%
-4.36
+11.82%
-4.94
Changes In Cash
10.95
+467.44%
-2.98
-182.18%
3.62
+111.87%
-30.54
Beginning Cash Position
20.01
-12.96%
22.98
+18.72%
19.36
-61.20%
49.90
End Cash Position
30.95
+54.71%
20.01
-12.96%
22.98
+18.72%
19.36
Free Cash Flow
-5.17
-200.82%
-1.72
+66.52%
-5.13
+82.21%
-28.82
Interest Paid Supplemental Data
2.82
-30.13%
4.04
+5.95%
3.81
+21.09%
3.15
Income Tax Paid Supplemental Data
1.42
-11.75%
1.61
0.00
—
Common Stock Issuance
14.84
+328.04%
3.47
-77.74%
15.57
+33.19%
11.69
Issuance Of Capital Stock
14.84
+328.04%
3.47
-77.74%
15.57
+33.19%
11.69
Sale Of Business
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category